SESSIONS DAY 1: Friday 5 Nov 2021

CLL 101: CLL Basics 

Epidemiology, Diagnosis, disease course and staging, Watch & wait, Treatment & relapse

Dr Brian Koffman, CLL Advocates Network Steering Committee, Executive VP and Chief Medical officer CLL Society, USA // Michael Rynne, CLL Advocates Network Steering Committee, Communications Officer CLL Ireland, Ireland // Pierre Aumont, CLL Advocates Network Steering Committee (vice-chair), ELLyE Board member, France

Opening – Welcome by the CLL Advocates Network

Nick York, CLL Advocates Network Steering Committee (chair) and Patient Advocacy Healthcare Liaison Officer at Leukaemia Care, UK

Medical Session #1: Diagnosis, Management, Active Surveillance (Watch and Wait) and 1st Line Treatments

Chair: Dr Brian Koffman, CLL Advocates Network Steering Committee Executive VP and Chief Medical officer CLL Society, USA

Introduction to Topic & Speakers
Speaker: Dr Brian Koffman, USA

The Diversity of CLL (skip to 02:10 on video above)
The heterogeneity of CLL, i.e. variations of types of CLL and the influence of age, genetics, ethnics, gender, disease state, treatment, complications and co-morbidities, etc.
Speaker: Dr Versha Banerji, Associate Professor / University of Manitoba, Clinician Scientist / CancerCare Manitoba, Canada

Diagnosis and Active Surveillance (skip to 19:35 on video above)
Understanding the challenges and supporting the needs of those affected by CLL during diagnosis and “Watch and Wait”
Speaker: Dr Alina Gerrie, Assistant Professor, Hematology and Medical Oncology, University of British Columbia, Vancouver, Canada

First Line Treatment Update (skip to 35:56 on video above)
Current CLL treatment and management guidelines, new developments and issues
Speaker: Dr Nicole Lamanna, Associate Attending, Leukemia Service, Director of the Chronic Lymphocytic Leukemia Program, Hematologic Malignancies Section Herbert Irving Comprehensive Cancer Center, New York, USA

Question and Answer Session (skip to 58:44 on video above)
Moderator: Dr Brian Koffman, USA
Panel:
• Dr Alina Gerrie, Canada
• Dr Nicole Lamanna, USA
• Prof Paolo Ghia, Professor of Medical Oncology, Università Vita-Salute San Raffaele, Milano, Italy

Panel Discussion: Managing Emotional & Psychological Challenges of Living with a CLL Diagnosis (skip to 1:22:55 on video above)
Moderator: Charlotte Martin, Patient Advocacy Manager at Leukaemia Care, UK
Panel:
• Anne Crook, Counsellor / Psychotherapist, Psycho-oncology, The Christie NHS Foundation Trust, Manchester, UK
• Pierre Aumont, CLL Advocates Network Steering Committee (vice-chair), ELLyE Board member, France
• Jan Rynne, cofounder of CLL Ireland, Ireland

Advocacy Session # 1 – Evidence-Based Advocacy: Creating Evidence for Advocacy Impact

Chair: Jan Geissler, Patient Advocate, co-founder of the CML Advocates Network and chair of Leukaemie-Online, Germany

Introduction to Topic & Speakers
Speaker: Jan Geissler, Germany

Evidence-Based Advocacy: What’s behind the buzzword, and why is it important? (skip to 02:00 on video above)
Speaker: Zack Pemberton-Whiteley, Chief Executive Officer Leukaemia Care, UK

Understanding Evidence-Based Research Methods: Developing and Conducting Effective Surveys (skip to 20:10 on video above)
Speaker: Daniel Ratchford, Head of Quality Health, IQVIA Healthcare, UK

The Results of CLLAN’s Global CLL Resource Mapping & Unmet Needs Survey (skip to 38:38 on video above)
Speakers:
• Deborah Baker, CLL Advocates Network Steering Committee, CLL Canada Honorary Board member, Canada
• Michael Rynne, CLL Advocates Network Steering Committee, CLL Ireland, Ireland

Question and Answer Session (skip to 54:48 on video above)
Moderator: Jan Geissler, Germany
Panel:
• Zack Pemberton-Whiteley, UK
• Daniel Ratchford, UK
• Deborah Baker, Canada
• Michael Rynne, Ireland

CLL Horizons 2021 – Closure Day 1 & Outlook Day 2

Nick York, CLL Advocates Network Steering Committee (chair) and Patient Advocacy Healthcare Liaison Officer at Leukaemia Care, UK